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Abstract 
CYS ZM of cytochrome P45Oscc (CYPllAl) was selectively labelled with diiodofluorescein iodacetamide in solution and in proteoliposomes. The 
lahelling affected the interaction of P45Oscc with adrenodoxin and significantly inhibited the side-chain cleavage activity of the soluble and 
membrane-bound hemeprotein in the reconstituted system. In proteoliposomes both the labelled and unlabelled hemepoteins were susceptible to 
trypsin and split into Fl and F2, two fragments corresponding to the two main domains of P45Oscc. These results suggest hat the hinge connecting 
the two domains in the region Arg?4&’ 1s exposed to the surface of the membrane and involved in the interaction of P45Oscc with adrenodoxin. 
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nal cortex 
1. Introduction 
The transformation of cholesterol (CHL) to pregne- 
nolone (PG), the first step of adrenocortical ster- 
oidogenesis, is catalyzed by cytochrome P45Oscc 
(CYPllAl) localized in the inner mitochondrial mem- 
brane. For catalysis P45Oscc requires two electron trans- 
fer components, i.e. NADPH-adrenodoxin reductase 
(AR) and adrenodoxin (AD), the latter interacting di- 
rectly with the hemeprotein [1,2]. The P45Oscc molecule 
contains two cysteine residues, i.e. CYSTS (Cys303 for the 
signal peptide-containing precursor) and Cys”* (CYSTIC). 
The latter acts as the fifth ligand of the heme [3], whereas 
the function of the former is unknown. 
We previously used antibodies against intact P45Oscc 
molecule and its two tryptic fragments, Fl (Ile1-Ar~50) 
and F2 (Asn257-Ala48’), to study the topology of the 
hemeprotein in the inner mitochondrial membrane [4,5]. 
In this paper we studied the functional importance of the 
central region of the P45Oscc sequence, which includes 
the trypsin-sensitive, interdomain hinge, and the topol- 
ogy of the region in proteoliposomes by using diio- 
*Corresponding author. Fax: (7) (172) 636 772. 
Abbreviations: PC, phosphatydyl choline; PE, phosphatydyl etha- 
nolamine; CL, cardiolipin; DTT, 1,4,-dithiotreitol. 
dofluorescein iodoacetamide (DIFIA)-labelled CYSTS as 
a reference marker. 
2. Materials and methods 
2.1. Chemicals and proteins 
Sodium cholate, CHL, PG, cholestenon, progesterone, NADPH, 
Tween 20, trypsin, soybean trypsin inhibitor, protease from S. aureus 
V8, choleterol oxidase from Nocardia erythropolis, molecular weight 
standards for electrophoresis, and CL were all from Serva (Germany). 
Other lipids were from Lipid Products (UK). Guanidinium chloride, 
maleic acid anhydride, iodacetamide, DTT, solvents for HPLC were 
from Merck (Germany). Sepharose 4B, Sephadex G-25M, Sephacryl 
S-1000 were from Pharmacia (Sweden). Diiodofluorescein iodoacet- 
amide (DIFIA) was synthesized according to [6] and kindly provided 
by Prof. A. Stier (Max Planck Institute for Biophysical Chemistry, 
Gottingen, Germany). P45Oscc, AD and AR were purified from bovine 
adrenocortical mitochondria to electrophoretic homogeneity using spe- 
cific aBinity adsorbents 171. Antibodies against P45Oscc and its peptide 
fragments Fl and F2 were raised in rabbits and purified according to 
the procedure described earlier [4]. 
2.2. Labelling procedures 
Labelling of P45Oscc was performed in 50 mM potassium phosphate 
buffer, pH 7.2, containing 0.15% sodium cholate, 0.5 M NaCl, 0.5 mM 
EDTA, 10% glycerol and 0.2% methanol (labelling buffer). P45Oscc 
(200 mnol) and DIFIA (2 pmol) were mixed in a final volume of 5 ml. 
Incubation was carried out at 4°C for 10 h and then at 23°C for 1 h. 
After incubation, the mixture was applied to a Sephadex G-25M col- 
umn (2.5 x 12 cm) equilibrated with 50 mM sodium phosphate buffer 
(PB), pH 7.2, containing 20% glycerol (storage buffer) to remove the 
free label. The amount of noncovalently bound label in the tinal prep- 
aration was estimated by SDS-PAGE followed by scanning of the 
fluorescent bands by a Shimadzu Gel scanner GS-9000 at 517 mu. 
0014-5793/94/$7.00 0 1994 Federation of European Biochemical Societies. All rights reserved. 
SSDI 0014-5793(94)00085-A 
84 A. Chernogolov et al. IFEBS Letters 340 (1994) 83-88 
P45Oscc incorporated into liposomes was labelled in 50 mM PB, pH 
7.4, containing 0.1 M NaCl, 0.5 mM EDTA, 0.1 mM DTT and 20% 
glycerol (standard buffer). For labelling, 16 ~1 of the stock solution of 
DIFIA in the same buffer (DIFIA concentration of 2.353 mM) was 
added to 100 ~1 of a suspension of P450scc-containing liposomes 
(P45Oscc oncentration, 37 PM). The mixture was incubated at 4°C for 
8 h and then at 23°C for 30 min. Subsequently the sample was applied 
to a Sephadex G-25M column (0.4 x 2.5 cm) equilibrated with the same 
buffer. Protein-free liposomes were treated with DIFIA under the same 
conditions to assess possible nonspecific incorporation or adsorption 
of the label to the membrane. 
2.3. Incorporation of P45Oscc into liposomes 
P45Oscc and DIFIA450scc were incorporated into unilamellar li- 
posomes (PC/PE/CL/CHL, 2 : 2 : 1: 0.6 by weight) by means of octylglu- 
coside dialysis. A lipid mixture containing egg PC (3.5 mg), egg PE (3.5 
mg), bovine heart CL (1.8 mg) and CHL (1.1 mg) was dried and then 
dissolved in 9 ml (final volume) of 50 mM potassium phosphate buffer, 
pH 7.4, containing 100 mM KCl, 0.5 mM EDTA, 0.1 mM DTT, 20% 
glycerol, 4 PM P45Oscc (or DIFIA-P450scc) and 0.43% octylglycoside 
(lipid/protein ratio, 5: 1 by weight). The mixture was dialysed at 4°C 
for 48 h against standard buffer in the presence of the Bio-Beads SM-2 
(Bio-Rad, USA). The dialysed mixture was then gel-filtrated and frac- 
tionated on Sephacryl S-1000 and fractions of largest vesicles were 
collected. Finally, the suspension of P450scoliposomes was concen- 
trated using a Centricon- microconcentrator (Amicon, USA) to a 
P45Oscc oncentration of 1630 FM. 
2.4. Interaction with adrenodoxin and enzymatic activity of DIFIA- 
P45Oscc 
Differential spectral titration of P45Oscc with AD was performed 
according to [8] in 50 mM PB, pH 7.4 containing 25 PM CHL and 
0.03% Tween 20 at 23°C. Defined amounts of AD were added from a 
stock solution to avoid final dilutions of the reaction mixtures greater 
than 4% [9]. 
CHL side chain cleavage activity of P45Oscc was determined in the 
reconstituted system as described earlier [4] followed by treatment of 
the reaction mixture with CHL oxidase to convert CHL and PG into 
the 3-one-4-en steroids, i.e. cholestenon and progesterone, respectively 
[lo]. The conversion reaction was initiated by addition of 50@ of CHL 
oxidase (0.4 U) in 20 mM potassium phosphate buffer, pH 7.4, contain- 
ing 1% sodium cholate, to 1 ml of the reaction mixture. After incubation 
at 37°C for 10 min, the steroids were extracted with dichloromethane. 
The extract was dried under a stream of nitrogen and analysed by 
reverse-phase HPLC on a Nucleosil-gel 5C,s column (4 x 100 mm; 
Macherey-Nagel, Germany) with a gradient solvent system of 70-100% 
of methanol. 
2.5. Proteolysis of soluble and membrane-bound DIFIA-P45Oscc with 
trypsin 
DIFIA-P450scc and DIFIA-P450scocontaining liposomes were di- 
luted with standard buffer up to a P45Oscc oncentration of 3 PM. 
Trypsin was added to the suspension up to the molar ratio P45Oscc/ 
trypsin of 50 : 1 or 20 : 1. The suspension was incubated for 30-60 min 
at 23°C and then soybean trypsin inhibitor added up to a ratio inhibi- 
tor/trypsin of 4: 1. The samples were incubated 60 min at 4°C. 2- 
Mercaptoethanol and SDS were added to the sample up to 5% and 2%, 
respectively. The sample was boiled for 3 min and then analysed by 
SDS-PAGE followed by immunoblotting in the presence of antibodies 
against P45Oscc and its fragments Fl and F2. 
2.6. Analytical methods 
SDS-PAGE was carried out according to Laemmli [l l] in a Bio-Rad 
Mini-Protean II Cell. To detect DIFIA-P450scc and its fragments after 
proteolysis, gels were scanned and processed by an imagination system 
consisting of Cromato-VUE Transilluminator TM-36 (UVP, USA) as 
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Fig. 1. Labelling of P45Oscc in solution with DIFIA. (- .. - .. -) intact P45Oscc in labelling buffer, (- - - -) DIFIA in labelling buffer; (-) 
DIFIA-P450scc in storage buffer. Inset: chemical structure of DIFIA. 
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an UV-light source and Mitsubishi video copy processor (Mitsubishi, 
Japan). After scanning the gel was stained with Coomassie BB R-250. 
Immunoblotting was performed in Bio-Rad Mini-Transblot apparatus 
according to the procedure described previously [4]. 
P45Oscc oncentrations were determined from the absolute spectra 
or from CO-difference spectra of dithionite-reduced preparations of 
liposomes using an extinction coefficient of 91 mM_’ . cm-’ at 393 or 
450 nm, respectively [12]. 
The amount of DIFIA bound to P45Oscc was determined from its 
characteristic absorbance at 517 nm using an extinction coefficient of 
75 mM_’ cd. 
Proteolysis of DIFIA-P450scc with S. aureus V8 protease was per- 
formed in 0.1 M ammonium bicarbonate buffer, pH 8.3, according to 
[ 131. Separation of the peptide products labelled with DIFIA was car- 
ried out by reverse-phase HPLC as described [14]. Structure analysis 
of the peptide fractions was carried out using a Gas-phase Sequenator 
477A from Applied Biosystem (USA) followed by on-line detection of 
the PTH-amino acids by HPLC according to standard programs. 
3. Results 
3.1. Labelling of P45Oscc with DIFIA 
Labelling of P45Oscc with DIFIA, an SH-specific fluo- 
rescent reagent, caused a shift of the absorption maxi- 
mum of the fluorophore from 512 nm to 516518 nm 
(Fig. 1). The use of 50 mM potassium phosphate buffer 
containing 0.5 M NaCl and 0.15% sodium cholate pre- 
vented the inactivation of P45Oscc and its conversion 
into the P420 state (confirmed by the reduced CO differ- 
ence spectrum) during the labelling procedure. After gel 
filtration of the labelled hemeprotein on Sephadex G- 
25M, the amount of noncovalently bound DIFIA de- 
creased to 7-9.5% as determined by SDS-PAGE fol- 
lowed by absorbance scanning at 517 nm. On the other 
hand, in P45Oscc labelled with diiodofluorescein isothio- 
cyanate, a lysine-specific, hydrophobic reagent, about 
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60% of the label was noncovalently bound even after gel 
filtration [15]. The DIFIA-P450scc prepared by the 
method described in section 2.2 contained about 1 mole 
of DIFIA per mole of the hemeprotein. When the la- 
belled protein was digested with S. aureus V8 protease 
and the peptide fragments were separated by HPLC, 
only one major labelled peptide (absorbing at 517 nm) 
was obtained and its sequence was determined to 
be Phe-Arg-Asn-Tyr-Pro-Gly-Ile-Leu-Tyr-Cys(*)-Leu- 
Leu-Lys-Ser-Glu, where * indicates the position of the 
label. This peptide corresponds to the P45Oscc sequence 
Phe255G1u26g [16,17]. No other labelled peptides were 
found. It was therefore concluded that DIFIA specifi- 
cally modifies Cys*@’ leaving the second cysteine residue 
cys422 unlabelled and that the central region of P45Oscc 
including CYSTS is accessible for the chemical modifica- 
tion under the conditions employed. Treatment of lipo- 
somal bound P45Oscc with DIFIA also resulted in spe- 
cific labelling of the hemeprotein (data not shown). How- 
ever, the final DIFIA/P450scc molar ratio was only 0.5- 
0.6. Neither an increase in the incubation time nor the 
use of a large excess of DIFIA enhanced the amount of 
bound DIFIA. 
3.2. Interaction of DIFIA-P45Oscc with AD 
Although DIFIA labelling of P45Oscc did not change 
the structure around the heme significantly (monitored 
by EPR spectroscopy of the heme iron, not shown) and 
did not convert the hemeprotein into the P420 state, the 
labelling affected the interaction of P45Oscc with AD. 
Fig. 2A shows the results of spectral titration of P45Oscc 
with AD, indicating that AD binds to the hemeprotein 
with a spectral dissociation constant (K,) of 3.8 ,uM. 
Wavelength (nm) 
Fig. 2. Spectrophotometric titration of intact P45Oscc (A) and DIFIA-P45Oscc (molar ratio 1: 1) (B) The concentration of P45Oscc was 2.3 PM. AD 
was sequentially added up to the final concentrations 3.4, 10.4, 17.3 and 24.2 PM. 
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Fig. 3. Enzymatic activity of DIFIA-P45Oscc preparations with different molar ratio of labelling. The reconstituted system contained in a final volume 
of 1 ml 0.5 ,uM P45Oscc or DIFIA-P450scc, 0.4 PM of AR, 100 PM CHL, 360 ,uM NADPH and 2.5 ,uM (line 1) or 5 pM (line 2) AD in 50 mM 
PB, pH 7.4, containing 0.2% Tween 20. The activity of intact P45Oscc is 5.3 nmol of PG/nmol of P450scc/min for the molar ratio ADIP450scc of 
5 : 1 (line 1) and 6.6 nmol of PG/nmol of P450scc/min for the rato 10: 1 (line 2). 
When DIFIA-P450scc was used, the spectral change in- 
duced by AD binding was significantly diminished with 
a K, value of 6.0 ,uM (Fig. 2B). The maximal spectral 
change was also decreased 1.6-fold by the labelling. It 
was thus evident that DIFIA labelling significantly re- 
duces the capacity of P45Oscc to interact with AD. 
3.3. Effect of DIFIA labelling on the reconstituted enzyme 
activity 
Since DIFIA labelling of P45Oscc decreases its ability 
to bind AD, it is not surprising that the labelling also 
affected its CHL side-chain cleavage activity in the re- 
constituted system. The inhibitory effect depends on 
both the amount of DIFIA bound to P45Oscc and the 
AD/P450scc molar ratio in the reaction mixture (Fig. 3). 
A lo-fold excess of AD almost prevents the inhibition, 
but at a ratio AD/P450scc of 5 the activity of DIFIA- 
P45Oscc (1: 1 molar ratio) was only 53% of that of the 
intact hemeprotein. We next measured the activities of 
variously composed reconstituted systems consisting of 
NADPH, AR, AD and (1) intact P45Oscc, (2) DIFIA- 
P45Oscc (1: l), (3) DIFIA-P450scc-containing li- 
posomes, (4) P450scc-containing liposomes, or (5) 
P450scc-containing liposomes treated with DIFIA after 
incorporation of the hemeprotein into the vesicles (final 
DIFIA/P450scc ratio = 0.51). As shown in Table 1, lipo- 
somal bound intact P45Oscc an catalyze the conversion 
of CHL to PG more effectively (81% stimulation) than 
in solution. Treatment of liposomal bound P45Oscc with 
DIFIA inhibited the activity by 38%. On the other hand, 
liposomes containing P45Oscc that had been labelled 
(DIFIA/P450scc molar ratio = 1) before incorporation 
into vesicles retained only 32% of the activity as com- 
pared to liposomes containing intact P45Oscc. 
3.4. Tryptic digestion of soluble and liposomal bound 
DIFIA-P45Oscc 
Limited tryptic digestion of DIFIA-P450scc (molar 
ratio 1: 1) led to the formation of two main peptide frag- 
ments having apparent molecular masses between 26,000 
and 29,000 Da as estimated by SDS-PAGE (Fig. 4B, 
lanes 6 and 7). Only one of these fragments having lowest 
molecular mass was fluorescent (Fig. 4A, lanes 6 and 7). 
These molecular masses correspond to those of the frag- 
ments Fl (Ile’-Arg2”) and F2 (Asn2s7-Ala481) (Fig. 4B, 
lanes 1 and 2), which were previously detected after tryp- 
sinolysis of unlabelled P45Oscc [18]. Soybean trypsin in- 
hibitor inhibited the formation of F 1 and F2 from intact 
P45Oscc (Fig. 4B, lanes 3 and 4). Separation of the tryp- 
sin digest of DIFIA-P450scc by SDS-PAGE followed by 
immunoblotting with antibodies raised against Fl and 
F2 actually showed that the fragments were reactive with 
the antibodies (not shown). Limited trypsinolysis of lipo- 
somal bound intact P45Oscc followed by SDS-PAGE 
revealed that the hemeprotein was digested to Fl and F2 
to a comparable xtent as unbound P45Oscc (not shown). 
Labelling of liposomal bound P45Oscc with DIFIA and 
subsequent trypsin digestion (not shown) as well as tryp- 
sinolysis of liposomal bound DIFIA-P450scc (1: 1) (Fig. 
4B, lanes 8 and 9) also gave similar eletrophoretic pat- 
terns on SDS-PAGE. In all these cases, immunoblotting 
using anti-F1 and anti-F2 antibodies showed that the 
label was detectable only in F2. These results indicate 
that the hinge region (Arg250-Asn257) of intact and 
DIFIA-modified P45Oscc is accessible to trypsin both in 
solution and in proteoliposomes. It can also be con- 
cluded that labelling of P45Oscc with DIFIA does not 
influence the intramolecular location of this hinge re- 
gion. 
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Fig. 4. Limited proteolysis of soluble and membrane-bound DIFIA-P450scc with trypsin. (A) unstained 12% PAGE SDS-electrophoresis slab 
photographed under UV light. (B) the slab stained with Coomassie BB R-250. Samples contained equal amounts of: 1, soluble P45Osc.c treated with 
trypsin at molar ratio P450scc/trypsin of 50 : 1 for 30 min; 2, as 1 (the ratio 20: 1,60 min); 3 and 4, P45Oscc preincubated with soybean trypsin inhibitor 
and after that treated with trypsin under the conditions of the samples 1 and 2, respectively; 5, molecular weight standards (shown in Da); 6 and 
7, DIFIA-P450scc with molar ratio of the labelling 1: 1 treated with trypsin under the conditions of the samples 1 and 2, respectively; 8 and 9, 
DIFIA-P450scc proteoliposomes treated with trypsin under the same conditions; 10, DIFIA-P450scc; 11, soluble P45Oscc; 12, molecular weight 
standards as in 5 + pure DIFIA. The samples containing P45Oscc and DIFIA-P450scc were taken in highest excess to be analysed by UV scanning. 
4. Discussion 
Despite numerous studies on membrane-bound P450- 
dependent oxygenase systems (for review see [I ,2,19]), 
little is known of the mechanism of inner mitochondria 
membrane-associated electron transfer from AR to 
P45Oscc via AD and the topology of the hemeprotein in 
the membrane. Based on studies on limited proteolysis 
of the inner mitochondrial membrane and immunochem- 
ical assay of P45Oscc, we have recently suggested that 
P45Oscc penetrates the membrane and the trypsin-sensi- 
Table 1 
Enzymatic activity of membrane-bound P45Oscc and DIFIA-P450scc* 
Preparation Activity 8 
(nmol of PG/nmol 
of P45Oscc/min) 
P45Oscc-liposomes 
P45Oscoliposomes labelled 
4.73 181.0 
with DIFIA (1: 0.51) 
DIFIA-P450scc (1: 1) 
2.94 112.6 
liposomes 
DIFIA-P450scc (1: 1) in 
1.53 58.6 
solution 1.23 47.1 
P45Oscc (intact) in solution 2.61 100.0 
*P45Oscc and DIFIAP450scc were incorporated into liposomes con- 
sisting of PC/PE/CWCHL with a weight ratio 2:2:1:0.6. The reconsti- 
tuted system contained in a final volume of 1 ml: 0.5 PM P45Oscc, 4PM 
AD, 0.28 PM AR, 100 PM CHL and 360 pM of NADPH in 50 mM 
PB, pH 7.4 with 0.01% Tween 20. To prevent the solubilization of 
liposomes, the concentration of Tween 20 was decreased in comparison 
with the standard activity experiments described above for DIFIA- 
P45Oscc in aqueous solution (Fig. 3). 
tive hinge region (Arg 250-Asn257) is exposed to the mito- 
chondrial matrix space [5,7]. 
The results obtained in this work suggest hat the in- 
terdomain hinge in the P45Oscc sequence including 
cy? . IS directly involved in the interaction of hemepro- 
tein with AD on the surface of the liposomal membrane. 
It is also likely that this interaction occurs outside the 
phospholipid membrane between the hinge region, which 
is protruding to the outside, and externally added AD. 
However, it cannot as yet be decided whether CYSTS is 
directly involved in the interaction with AD or the inhi- 
bition of AD binding is due to a steric hindrance effect 
of the relatively bulky DIFIA molecule. Taken together, 
the results described above provide evidence that (1) 
Cys’” of P45Oscc an be specifically labelled with DIFIA 
without changing the basic structure of the hemeprotein, 
(2) Cy?@ . IS located at or near the AD binding area, and 
(3) this area is exposed to the outer surface of the lipo- 
somal membrane and accessible to AD added externally. 
It should be noted that the central region of the bovine 
P45Oscc sequence contains two lysine residues, i.e. LYS~~’ 
and LYS~‘~, which have been identified by chemical mod- 
ification with succinic anhydride as being involved in AD 
binding through charge ion pairing [14]. It has also been 
found that the P45Oscc sequence Leu266-Leu272 is one of 
the antigenic determinants of the P45Oscc molecule [20] 
and antibodies against P45Oscc and F2 fragment have 
been shown to strongly inhibit the CHL side-chain cleav- 
age activity of P45Oscc [4]. 
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